JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gaou, I.
Right arrow Articles by Fromenty, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gaou, I.
Right arrow Articles by Fromenty, B.

Vol. 297, Issue 2, 516-523, May 2001

Effect of Stavudine on Mitochondrial Genome and Fatty Acid Oxidation in Lean and Obese Mice

Isabelle Gaou, Miriam Malliti, Marie-Christine Guimont, Philippe Lettéron, Christine Demeilliers , Gilles Peytavin, Claude Degott, Dominique Pessayre and Bernard Fromenty

Institut National de la Santé et de la Recherche Médicale Unité 481 and Centre Claude Bernard de Recherches sur les Hépatites Virales (I.G., M.M., P.L., C.D., D.P., B.F.), Service de Biochimie (M.-C.G.), Service Central d'Anatomie et de Cytologie Pathologiques (C.D.), Hôpital Beaujon, Clichy, France; and Pharmacie, Hôpital Bichat, Paris, France (G.P.)

Like other antihuman immunodeficiency virus dideoxynucleosides, stavudine may occasionally induce lactic acidosis and perhaps lipodystrophy in metabolically or genetically susceptible patients. We studied the effects of stavudine on mitochondrial DNA (mtDNA), fatty acid oxidation, and blood metabolites in lean and genetically obese (ob/ob) mice. In lean mice, mtDNA was depleted in liver and skeletal muscle, but not heart and brain, after 6 weeks of stavudine treatment (500 mg/kg/day). With 100 mg/kg/day, mtDNA transiently decreased in liver, but was unchanged at 6 weeks in all organs, including white adipose tissue (WAT). Despite unchanged mtDNA levels, lack of significant oxidative mtDNA lesions (as assessed by long polymerase chain reaction experiments), and normal blood lactate/pyruvate ratios, lean mice treated with stavudine for 6 weeks had increased fasting blood ketone bodies, due to both increased hepatic fatty acid beta -oxidation and decreased peripheral ketolysis. In obese mice, basal WAT mtDNA was low and was further decreased by stavudine. In conclusion, stavudine can decrease hepatic and muscle mtDNA in lean mice and can also cause ketoacidosis during fasting without altering mtDNA. Stavudine depletes WAT mtDNA only in obese mice. Fasting and ketoacidosis could trigger decompensation in patients with incipient lactic acidosis, whereas WAT mtDNA depletion could cause lipodystrophy in genetically susceptible patients.


0022-3565/01/2972-0516$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
I. Larosche, P. Letteron, B. Fromenty, N. Vadrot, A. Abbey-Toby, G. Feldmann, D. Pessayre, and A. Mansouri
Tamoxifen Inhibits Topoisomerases, Depletes Mitochondrial DNA, and Triggers Steatosis in Mouse Liver
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 526 - 535.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
R. Note, C. Maisonneuve, P. Letteron, G. Peytavin, F. Djouadi, A. Igoudjil, M.-C. Guimont, M. Biour, D. Pessayre, and B. Fromenty
Mitochondrial and Metabolic Effects of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in Mice Receiving One of Five Single- and Three Dual-NRTI Treatments
Antimicrob. Agents Chemother., November 1, 2003; 47(11): 3384 - 3392.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
R. V. Sekhar, F. Jahoor, A. C. White, H. J. Pownall, F. Visnegarwala, M. C. Rodriguez-Barradas, M. Sharma, P. J. Reeds, and A. Balasubramanyam
Metabolic basis of HIV-lipodystrophy syndrome
Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E332 - E337.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.